scholarly journals The pharmacoepidemiological analysis of the influenza pharmacotherapy in Ukraine

2021 ◽  
pp. 54-59
Author(s):  
O. Balitska ◽  
V. Zlahoda ◽  
Yu. Hryhoruk ◽  
O. Cordon
Keyword(s):  
Total Population ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Antiviral Drugs ◽  
Medical Attention ◽  
Epidemic Season ◽  
State Register ◽  
Trade Names ◽  
Effective Drugs ◽  
Production Company

Influenza and other acute respiratory viral infections (ARIs) are the most common among human diseases that require timely medical attention and treatment with the most effective drugs. The aim of the study is pharmacoepidemiological analysis of drugs for the treatment of influenza registered in Ukraine. Materials and methods of research. The study was based on data from the State Register of Medicines of Ukraine, information on the results of the epidemic season of influenza and acute respiratory infections of the Center for Public Health of the Ministry of Health of Ukraine, declared drugs under the International Nonproprietary or Common Name in Ukraine as of January 2021.  Methods: retrospective, descriptive and frequency analyzes. Results and discussion. A pharmacoepidemiological analysis of influenza drugs in Ukraine was conducted. It was found that the incidence of influenza and SARS during the study period decreased by 3.1% of the total population. Fatalities due to influenza and SARS increased by 41 cases during the study period, which may be related to the coronavirus pandemic. According to the results of a marketing study of antiviral drugs, it was found that the largest share in the structure of registered trade names are interferons (11 trade names). Conclusions. The analysis of the market showed that among the antiviral drugs registered in Ukraine for the studied period the dominance of domestic drugs is noted - 54% (respectively of foreign origin - 46%). Analysis of the distribution of domestic analogues of antiviral drugs by manufacturers found that the largest (5 and 4 TN) belongs to LLC "Research and production company" Interpharmbiotek and FZ "Biopharma" Ltd., Ukraine, Bila Tserkva. Key words: influenza; pharmacoepidemiological analysis; antiviral drugs

scholarly journals Prospective Behavioral Study of Patients with Acute Respiratory Infections

2015 ◽  
Vol 14 (4) ◽  
pp. 36-40
Author(s):  
Z. Sh. Nurmatov
Keyword(s):  
Respiratory Infections ◽  
Incidence Rates ◽  
Medical Attention ◽  
Influenza Surveillance ◽  
Systematic Sampling ◽  
Acute Respiratory Infections ◽  
Behavioral Study ◽  
Regional Office ◽  
Epidemic Season ◽  
Catchment Population

Introduction: Review of official reports for the last 10 years revealed that up to 5% of the country population suffers from acute respiratory infections (ARI) annually. The study aimed to research the actual incidence by analyzing the prevailing behaviors in populations with respiratory symptoms.Methods: The prospective behavioral study was conducted at the outpatient clinic No 1 in Bishkek, with the number of catchment population aged above 18 totaling 25,057. Selection of respondents was based on systematic sampling. Every hundredth resident was selected from the electronic database of the catchment population. 224 people above 18 were actually enrolled in the study. The survey continued from November 2012 to April 2013. Except for the first interview, all follow-up interviews were done over the phone. For the purposes of the study, individuals in the study group were considered cases if they exhibited symptoms of ARI, according to the WHO Regional Office for Europe guidance for sentinel influenza surveillance in humans (2011). The survey results data analysis was performed using the Epi Info statistical software.Results: From November 2012, to April 2013, 61.2% (224) of the observed population became ill. 46.7% were ill with ARI once, 40.1% – 2 – 3 times, 11.7% – 4 – 7 times, as a result 137 people got sick a total of 307 times (136,161 per 100,000 population), only 75 cases sought medical attention (24.6%). The incidence rates in the observed group of patients with ARI (75/305) who sought medical care per 100,000 population comprised 33,482.1. According to the routine surveillance in 2012 – 2013 epidemic season, there were 34,637 cases of ARI (3,826.9 per 100,000 population). In the fall, the incidence totaled 36.8%, in winter – 20.2% and in spring 29.1%. The incidence rates by age group, gender, and presence of children in the family did not have statistically significant differences. The most frequent symptoms were as follows: cough (64.6%), rhinitis (61.0%), headache (58.1%), and sore throat (50.1%).Conclusions: In the 2012 – 2013 epidemic season, the incidence of ARI in the observed population was 35.6 times higher than the registered incidence in Bishkek, which indicates the low rate of seeking care. 

scholarly journals EFFICACY OF KAGOCEL IN NONSPECIFIC PREVENTION OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA

2019 ◽  
Vol 5 (3) ◽  
pp. 68-76
Author(s):  
Irina V. Ozerova ◽  
Nikolay A. Malishev
Keyword(s):  
Immune Response ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Antiviral Drug ◽  
Economic Cost ◽  
Antiviral Drugs ◽  
High Risk Group ◽  
Time Data ◽  
Direct Acting Antiviral ◽  
Respiratory Viral Infections

Acute respiratory viral infections (ARVI) are some of the most widely spread diseases worldwide that are of 80% of economic cost of infectious diseases. It is known that specific prophylaxis (vaccination) and, in some clinical cases, direct-acting antiviral prophylaxis are key strategies for the prevention of influenza as one of the most dangerous ARVI viruses. However, there are a number of reasons why specific prophylaxis of influenza does not entirely address the issue of prophylaxis of ARVI that are caused by more than 200 different viruses, such as formation of immune response only to vaccine influenza strains and absence of immune response to other respiratory infections, induction in the case of short-term protection, especially, in the aged and others. Prevention of influenza with antiviral drugs is limited by risks of development of resistant influenza strains aa well as contraindications and limitations of use. Therefore, the use of nonspecific drugs such as broad-spectrum antiviral drugs of interferon type (IFN) and their inducers (II), as well as sanitary and hygienic measures is recommended for prevention. For the purpose of prevention, the use of inducers of endogenic interferons is relevant in unvaccinated persons during pre-epidemic and epidemic ARVI periods; in high-risk group (students, medical professions, transport workers, elderly, patients with comorbid pathologies, people in structured organizations, for example, military personnel), in immunocompromised people. One of the most extensively studied interferon inducers widely used in clinical practice since 2003 for prevention and treatment of influenza and diseases caused by Herpesviruses is an antiviral drug Kagocel®. The paper presents real-time data of the preventive efficacy of Kagocel® in the therapy of acute respiratory viral infections and influenza caused by different viral strains including pandemic ones.

scholarly journals The role of influenza viruses in the development of severe acute respiratory infection in patients admitted to Yekaterinburg hospitals during 2017–2018 epidemic season

2020 ◽  
Vol 97 (2) ◽  
pp. 140-149
Author(s):  
Aleksandr V. Alimov ◽  
Svetlana S. Smirnova ◽  
Evgenia V. Lelenkova ◽  
Aleksandr Yu. Markaryan ◽  
Ivan V. Vyalykh ◽  
...  
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Influenza Viruses ◽  
Clinical Samples ◽  
Influenza B ◽  
Amino Acid Substitutions ◽  
Epidemic Season ◽  
Respiratory Viral Infections

Objective. To study the role of influenza viruses in the development of severe acute respiratory infections (SARI) in patients admitted to Yekaterinburg hospitals during 2017-2018 epidemic season.Materials and Methods. A retrospective epidemiological analysis of influenza incidence in Yekaterinburg was conducted, 403 influenza and acute respiratory viral infections case sheets were studied, and PCR analysis of clinical samples from the patients for respiratory viral infections was performed.Results. During the epidemic period a total 27.0% of the Yekaterinburg population were reported with influenza and other SARI, with 1.8% patients hospitalized. 5.6% of the total number of patients admitted with influenza and SARI in Yekaterinburg hospitals were included in the study. The rate of the detection of influenza A and B viruses RNA in the clinical samples from the patients with SARI was 28.3%. The rates of the detection in PCR of influenza B/Yamagata, A(H1N1)pdm09 and A(H3N2) were 46.5, 20.2 and 10.5%, respectively.Conclusion. The study results indicated that influenza viruses remain significant pathogens of respiratory infections that required hospitalization. Among patients with SARI the highest incidence was observed in children of a younger age group and was mainly associated with influenza B virus of Yamagata lineage and influenza A virus (H1N1)pdm09. According to the results of a molecular genetic study, influenza A (H1N1) pdm09 viruses belonged to clade 6B.1, carried characteristic amino acid substitutions in hemagglutinin S84N, S162N (with the acquisition of a potential glycosylation site) and I216T and were similar to the A/Michigan/45/2015 vaccine strain. The influenza B viruses studied belonged to the Yamagata lineage, clade 3. The influenza B/Ekaterinburg /RII-4723S/2018 virus differed from the reference strain B/Phuket/3073/2013 by two amino acid substitutions in the hemagglutinin gene M251V and L172Q.

Structural analysis of drugs assortment for etiopathogenetic therapy of children with acute viral infections

2020 ◽  
Vol 2 (2) ◽  
pp. 20-28
Author(s):  
Igor A. Narkevich ◽  
Oksana D. Nemyatykh ◽  
Vladimir N. Timchenko ◽  
Dina D. Siukaeva ◽  
Taisia M. Terninko ◽  
...  
Keyword(s):  
Data Aggregation ◽  
Viral Infections ◽  
Analysis Data ◽  
Dosage Forms ◽  
National Registry ◽  
Research Information ◽  
State Register ◽  
The Russian Federation ◽  
Trade Names ◽  
Medicines For Children

The purpose evaluated the range of drugs for the etiopathogenetic treatment of children with acute viral infections. The methods of content analysis, data aggregation, comparative analysis are used. The research information base was made up of State Register of Medicines and National Registry of Medicines data as of 26 November 2019, as well as instructions for the medical use of drugs. It is shown that in the Russian Federation 201 trade names of drugs (35 INN) and 57 substances are registered. The leading positions in the structure of the supply of drugs and substances are held by russian manufacturers (76,00% and 70,00%, respectively). At the same time, structuring by dosage forms allows one to isolate tablets and powders (39,00% and 78,00% for finished dosage forms and substances, respectively). Acyclovir prevails in the structure of the range of medicines (25,00% and 19,00% for international non-proprietary and trade names, respectively). The largest share in the structure of the assortment of substances is covered by interferon alfa-2b (17,50%). The results of the analysis demonstrate that for most drugs, the manufacturer carries out all stages of production, including issuing quality control (67,00%). For 2015-2019, the renewal index of the assortment of the study group was 22,38%. Given the uncontrolled increase in the incidence rate, the presented assortment of antiviral and immunomodulating agents is sufficient to satisfy the needs of Russian pediatrics. One of the promising vectors for the development of the pharmaceutical industry in terms of providing medicines for children with acute viral infections is the development of drugs in the form of children's corrected forms.

Nucleosides and Nucleoside Analogues as Emerging Antiviral Drugs

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohamed Ibrahim Elzagheid
Keyword(s):  
Significant Role ◽  
Mode Of Action ◽  
Crucial Role ◽  
Viral Infections ◽  
Antiviral Drugs ◽  
Review Article ◽  
Nucleoside Analogues ◽  
The Past ◽  
Nucleoside Drugs

: Nucleosides and their analogues have been in use for many years and have become essential for treating patients with viral infections. Many additional nucleoside drugs have been approved over the past decades. This strongly demonstrates how important these compounds are and the crucial role they play. Given that a significant amount of research and literature has been documented regarding nucleoside analogues, this review article mainly focuses the discussion on nucleosides and nucleoside analogous that have proven to play significant role or be emerging in the treatment of known viral infections. This covers the names, structures, applications, toxicity, and mode of action of relevant nucleoside analogues.

scholarly journals Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab

Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 348
Author(s):  
Francesco Menzella ◽  
Giulia Ghidoni ◽  
Carla Galeone ◽  
Silvia Capobelli ◽  
Chiara Scelfo ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Severe Asthma ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Antiviral Effect ◽  
Point Of View ◽  
Type I ◽  
Effector Cells ◽  
Viral Spread ◽  
Increased Risk

Viral respiratory infections are recognized risk factors for the loss of control of allergic asthma and the induction of exacerbations, both in adults and children. Severe asthma is more susceptible to virus-induced asthma exacerbations, especially in the presence of high IgE levels. In the course of immune responses to viruses, an initial activation of innate immunity typically occurs and the production of type I and III interferons is essential in the control of viral spread. However, the Th2 inflammatory environment still appears to be protective against viral infections in general and in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections as well. As for now, literature data, although extremely limited and preliminary, show that severe asthma patients treated with biologics don’t have an increased risk of SARS-CoV-2 infection or progression to severe forms compared to the non-asthmatic population. Omalizumab, an anti-IgE monoclonal antibody, exerts a profound cellular effect, which can stabilize the effector cells, and is becoming much more efficient from the point of view of innate immunity in contrasting respiratory viral infections. In addition to the antiviral effect, clinical efficacy and safety of this biological allow a great improvement in the management of asthma.

scholarly journals 143. Initial Impact of COVID-19 on Ambulatory Antibiotic Prescribing for Respiratory Viral Infections

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S82-S82
Author(s):  
Zahra Kassamali Escobar ◽  
Todd Bouchard ◽  
Jose Mari Lansang ◽  
Scott Thomassen ◽  
Joanne Huang ◽  
...  
Keyword(s):  
Primary Care ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Urgent Care ◽  
Antibiotic Prescribing ◽  
Specific Rate ◽  
Inclusion Criteria ◽  
Diagnosis Codes ◽  
Control And Prevention ◽  
Viral Respiratory Infections

Abstract Background Between 15–50% of patients seen in ambulatory settings are prescribed an antibiotic. At least one third of this usage is considered unnecessary. In 2019, our institution implemented the MITIGATE Toolkit, endorsed by the Centers for Disease Control and Prevention to reduce inappropriate antibiotic prescribing for viral respiratory infections in emergency and urgent care settings. In February 2020 we identified our first hospitalized patient with SARS-CoV(2). In March, efforts to limit person-to-person contact led to shelter in place orders and substantial reorganization of our healthcare system. During this time we continued to track rates of unnecessary antibiotic prescribing. Methods This was a single center observational study. Electronic medical record data were accessed to determine antibiotic prescribing and diagnosis codes. We provided monthly individual feedback to urgent care prescribers, (Sep 2019-Mar 2020), primary care, and ED providers (Jan 2020 – Mar 2020) notifying them of their specific rate of unnecessary antibiotic prescribing and labeling them as a top performer or not a top performer compared to their peers. The primary outcome was rate of inappropriate antibiotic prescribing. Results Pre toolkit intervention, 14,398 patient visits met MITIGATE inclusion criteria and 12% received an antibiotic unnecessarily in Jan-April 2019. Post-toolkit intervention, 12,328 patient visits met inclusion criteria and 7% received an antibiotic unnecessarily in Jan-April 2020. In April 2020, patient visits dropped to 10–50% of what they were in March 2020 and April 2019. During this time the unnecessary antibiotic prescribing rate doubled in urgent care to 7.8% from 3.6% the previous month and stayed stable in primary care and the ED at 3.2% and 11.8% respectively in April compared to 4.6% and 10.4% in the previous month. Conclusion Rates of inappropriate antibiotic prescribing were reduced nearly in half from 2019 to 2020 across 3 ambulatory care settings. The increase in prescribing in April seen in urgent care and after providers stopped receiving their monthly feedback is concerning. Many factors may have contributed to this increase, but it raises concerns for increased inappropriate antibacterial usage as a side effect of the SARS-CoV(2) pandemic. Disclosures All Authors: No reported disclosures

scholarly journals Innate Immunity in Children and the Role of ACE2 Expression in SARS-CoV-2 Infection

2021 ◽  
Vol 13 (3) ◽  
pp. 363-382
Author(s):  
Mario Dioguardi ◽  
Angela Pia Cazzolla ◽  
Claudia Arena ◽  
Diego Sovereto ◽  
Giorgia Apollonia Caloro ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Viral Disease ◽  
Receptor Expression ◽  
Virus Infections ◽  
Search Terms ◽  
Bibliographic Search ◽  
Meta Analyses

COVID-19 (Coronavirus Disease 2019) is an emerging viral disease caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which leads to severe respiratory infections in humans. The first reports came in December 2019 from the city of Wuhan in the province of Hubei in China. It was immediately clear that children developed a milder disease than adults. The reasons for the milder course of the disease were attributed to several factors: innate immunity, difference in ACE2 (angiotensin-converting enzyme II) receptor expression, and previous infections with other common coronaviruses (CovH). This literature review aims to summarize aspects of innate immunity by focusing on the role of ACE2 expression and viral infections in children in modulating the antibody response to SARS-CoV-2 infection. This review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles deemed potentially eligible were considered, including those dealing with COVID-19 in children and providing more up-to-date and significant data in terms of epidemiology, prognosis, course, and symptoms, focusing on the etiopathogenesis of SARS-CoV-2 disease in children. The bibliographic search was conducted using the search engines PubMed and Scopus. The following search terms were entered in PubMed and Scopus: COVID-19 AND ACE2 AND Children; COVID-19 AND Immunity innate AND children. The search identified 857 records, and 18 studies were applicable based on inclusion and exclusion criteria that addressed the issues of COVID-19 concerning the role of ACE2 expression in children. The scientific literature agrees that children develop milder COVID-19 disease than adults. Milder symptomatology could be attributed to innate immunity or previous CovH virus infections, while it is not yet fully understood how the differential expression of ACE2 in children could contribute to milder disease.

scholarly journals Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic

2021 ◽  
Author(s):  
Bogna Grygiel-Górniak
Keyword(s):  
Connective Tissue ◽  
Viral Infections ◽  
Current Knowledge ◽  
Inflammatory Diseases ◽  
Antiviral Drugs ◽  
In Vivo Studies ◽  
Viral Diseases ◽  
Cardiac Complications

AbstractThe majority of the medical fraternity is continuously involved in finding new therapeutic schemes, including antimalarial medications (AMDs), which can be useful in combating the 2019-nCoV: coronavirus disease (COVID-19). For many decades, AMDs have been widely used in the treatment of malaria and various other anti-inflammatory diseases, particularly to treat autoimmune disorders of the connective tissue. The review comprises in vitro and in vivo studies, original studies, clinical trials, and consensus reports for the analysis, which were available in medical databases (e.g., PubMed). This manuscript summarizes the current knowledge about chloroquine (CQ)/hydroxychloroquine (HCQ) and shows the difference between their use, activity, recommendation, doses, and adverse effects on two groups of patients: those with rheumatic and viral diseases (including COVID-19). In the case of connective tissue disorders, AMDs are prescribed for a prolonged duration in small doses, and their effect is observed after few weeks, whereas in the case of viral infections, they are prescribed in larger doses for a short duration to achieve a quick saturation effect. In rheumatic diseases, AMDs are well tolerated, and their side effects are rare. However, in some viral diseases, the effect of AMDs is questionable or not so noticeable as suggested during the initial prognosis. They are mainly used as an additive therapy to antiviral drugs, but recent studies have shown that AMDs can diminish the efficacy of some antiviral drugs and may cause respiratory, kidney, liver, and cardiac complications.

scholarly journals Nanobiocide Based-Silver Nanomaterials Upon Coronaviruses: Approaches for Preventing Viral Infections

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Kamyar Khoshnevisan ◽  
Hassan Maleki ◽  
Hadi Baharifar
Keyword(s):  
Viral Entry ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Antiviral Agents ◽  
Long Term Stability ◽  
Silver Nanomaterials ◽  
Inhibitory Mechanisms ◽  
Low Toxicity ◽  
Nano Graphene

Abstract The effectiveness of silver nanomaterials (AgNMs), as antiviral agents, has been confirmed in humans against many different types of viruses. Nanobiocides-based AgNMs can be effectively applied to eliminate coronaviruses (CoVs), as the cause of various diseases in animals and humans, particularly the fatal human respiratory infections. Mostly, these NMs act effectively against CoVs, thanks to the NMs’ fundamental anti-viral structures like reactive oxygen species (ROS), and photo-dynamic and photo-thermal abilities. Particularly, the antiviral activity of AgNMs is clarified under three inhibitory mechanisms including viral entry limitation, attachment inhibition, and viral replication limitation. It is believed that nanobiocide with other possible materials such as TiO2, silica and, carbon NMs exclusively nano-graphene materials can emerge as a more effective disinfectant for long-term stability with low toxicity than common disinfectants. Nanobiocides also can be applied for the prevention and treatment of viral infections specifically against COVID-19. Graphic Abstract

Sign in / Sign up

Export Citation Format

Share Document